Background: Treatment of inflammatory bowel disease (IBD) in patients with prior malignancy is challenging because therapeutic immunosuppression required for controlling IBD activity may increase the risk of cancer recurrence. Key Messages: Contrary to the observations in the post-transplant population, retrospective observational studies of IBD patients with prior malignancy have not demonstrated that immunosuppressive drugs increased significantly the risk of new or recurrent cancer. However, these studies are highly biased and do not permit the use of these drugs. Factors like the time since treatment completion, severity, and subtype of prior cancer should be weighed along with the current IBD activity before choosing the best therapeutic strategy. In practice, most cases of prior cancer require a delay of at least 2 years before starting or resuming immunosuppressants, including anti-TNF agents. This delay should be extended to 5 years in cancer with a high risk of recurrence including cancer of the urinary tract, gastrointestinal cancer, leukemias, and multiple myeloma. A special attention should be paid to cancers with a high risk of late metastasis (breast, melanoma, renal cell carcinoma). Enteral nutrition, Budesonide, mesalamine, and limited intestinal resection should be considered following the completion of cancer treatment and prior to the safe initiation of immunosuppressive treatment for IBD. Thiopurines should be avoided in case of prior Epstein-Barr virus-related lymphoma, HPV-related carcinomas, and cancer of the urinary tract. Methotrexate and anti-TNF agents seem to be safe except for the risk of recurrent melanoma for the latter. Conclusion: IBD patients with prior malignancy should benefit from individual decisions made on a case-by-case basis.

1.
Beaugerie L: Management of inflammatory bowel disease patients with a cancer history. Curr Drug Targets 2014;15:1042-1048.
2.
Hemminki K, Li X, Sundquist J, Sundquist K: Cancer risks in Crohn disease patients. Ann Oncol 2009;20:574-580.
3.
Beaugerie L, Carrat F, Colombel JF, et al: Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. Gut 2014;63:1416-1423.
4.
Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al: Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011;141:1621-1628.e1-e5.
5.
Beaugerie L, Brousse N, Bouvier AM, et al: Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009;374:1617-1625.
6.
Bourrier A, Carrat F, Colombel JF, et al: Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Aliment Pharmacol Ther 2016;43:252-261.
7.
Abasolo L, Judez E, Descalzo MA, Gonzalez-Alvaro I, Jover JA, Carmona L: Cancer in rheumatoid arthritis: occurrence, mortality, and associated factors in a South European population. Semin Arthritis Rheum 2008;37:388-397.
8.
Solomon DH, Kremer JM, Fisher M, et al: Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs. Semin Arthritis Rheum 2014;43:489-497.
9.
Long MD, Martin CF, Pipkin CA, Herfarth HH, Sandler RS, Kappelman MD: Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 2012;143:390-399.e1.
10.
Salliot C, van der Heijde D: Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 2009;68:1100-1104.
11.
Mariette X, Matucci-Cerinic M, Pavelka K, et al: Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 2011;70:1895-1904.
12.
Beyaert R, Beaugerie L, Van Assche G, et al: Cancer risk in immune-mediated inflammatory diseases (IMID). Mol Cancer 2013;12:98.
13.
Penn I: The effect of immunosuppression on pre-existing cancers. Transplantation 1993;55:742-747.
14.
Terhorst D, Drecoll U, Stockfleth E, Ulrich C: Organ transplant recipients and skin cancer: assessment of risk factors with focus on sun exposure. Br J Dermatol 2009;161(suppl 3):85-89.
15.
Carretero G, Ferrandiz C, Dauden E, et al: Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry. J Eur Acad Dermatol Venereol 2015;29:156-163.
16.
Strangfeld A, Hierse F, Rau R, et al: Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 2010;12:R5.
17.
Axelrad J, Bernheim O, Colombel JF, et al: Risk of new or recurrent cancer in patients with inflammatory bowel disease and previous cancer exposed to immunosuppressive and anti-tumor necrosis factor agents. Clin Gastroenterol Hepatol 2016;14:58-64.
18.
Shelton E, Laharie D, Scott FI, et al: Cancer recurrence following immune-suppressive therapies in patients with immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology 2016;151:97-109.e4.
19.
Khoury W, Lavery IC, Kiran RP: Effects of chronic immunosuppression on long-term oncologic outcomes for colorectal cancer patients undergoing surgery. Ann Surg 2011;253:323-327.
20.
Kempen JH, Daniel E, Dunn JP, et al: Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ 2009;339:b2480.
21.
Mercer LK, Lunt M, Low AL, et al: Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British society for rheumatology biologics register for rheumatoid arthritis. Ann Rheum Dis 2015;74:1087-1093.
22.
Poullenot F, Seksik P, Beaugerie L, et al: Risk of incident cancer in inflammatory bowel disease patients starting anti-TNF therapy while having recent malignancy. Inflamm Bowel Dis 2016;22:1362-1369.
23.
Tookman AJ, Jones CL, DeWitte M, Lodge PJ: Fatigue in patients with advanced cancer: a pilot study of an intervention with infliximab. Support Care Cancer 2008;16:1131-1140.
24.
Jatoi A, Ritter HL, Dueck A, et al: A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9). Lung Cancer 2010;68:234-239.
25.
Wiedenmann B, Malfertheiner P, Friess H, et al: A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia. J Support Oncol 2008;6:18-25.
26.
Harrison ML, Obermueller E, Maisey NR, et al: Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. J Clin Oncol 2007;25:4542-4549.
27.
Larkin JM, Ferguson TR, Pickering LM, et al: A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma. Br J Cancer 2010;103:1149-1153.
28.
Raaschou P, Simard JF, Neovius M, Askling J: Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents. Arthritis Rheum 2011;63:1812-1822.
29.
Hamaguchi T, Wakabayashi H, Matsumine A, Sudo A, Uchida A: TNF inhibitor suppresses bone metastasis in a breast cancer cell line. Biochem Biophys Res Commun 2011;407:525-530.
30.
Papp K, Gottlieb AB, Naldi L, et al: Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry (PSOLAR). J Drugs Dermatol 2015;14:706-714.
31.
Luthra P, Peyrin-Biroulet L, Ford AC: Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease. Aliment Pharmacol Ther 2015;41:1227-1236.
32.
Chiu HY, Chen CH, Wu MS, Cheng YP, Tsai TF: The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C. Br J Dermatol 2013;169:1295-1303.
33.
Cosnes J: Crohn's disease phenotype, prognosis, and long-term complications: what to expect? Acta Gastroenterol Belg 2008;71:303-307.
34.
Munkholm P, Langholz E, Davidsen M, Binder V: Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995;30:699-706.
35.
Langholz E, Munkholm P, Davidsen M, Binder V: Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994;107:3-11.
36.
Rajca S, Seksik P, Bourrier A, et al: Impact of the diagnosis and treatment of cancer on the course of inflammatory bowel disease. J Crohns Colitis 2014;8:819-824.
37.
Bombardier C, Hazlewood GS, Akhavan P, et al: Canadian rheumatology association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety. J Rheumatol 2012;39:1583-1602.
38.
Singh JA, Furst DE, Bharat A, et al: 2012 update of the 2008 American college of rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64:625-639.
39.
Evans EB, Lin SY: New insights into tumor dormancy: targeting DNA repair pathways. World J Clin Oncol 2015;6:80-88.
40.
Rungoe C, Simonsen J, Riis L, Frisch M, Langholz E, Jess T: Inflammatory bowel disease and cervical neoplasia: a population-based nationwide cohort study. Clin Gastroenterol Hepatol 2015;13:693-700.e1.
41.
Kane S, Khatibi B, Reddy D: Higher incidence of abnormal pap smears in women with inflammatory bowel disease. Am J Gastroenterol 2008;103:631-636.
42.
Magro F, Peyrin-Biroulet L, Sokol H, et al: Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO pathogenesis scientific workshop (III). J Crohns Colitis 2014;8:31-44.
43.
Scott FI, Mamtani R, Brensinger CM, et al: Risk of nonmelanoma skin cancer associated with the use of immunosuppressant and biologic agents in patients with a history of autoimmune disease and nonmelanoma skin cancer. JAMA Dermatol 2016;152:164-172.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.